FDA chief vows tighter safety review of antidepressants in pregnancy and RSV protections for infants

TL;DR Summary
In her first staff address, FDA’s top drug regulator Tracy Beth Høeg pledges tougher safety monitoring of antidepressants used in pregnancy and RSV monoclonal antibodies for infants, signaling a broader push to reexamine oversight and encouraging staff to question norms.
Reading Insights
Total Reads
1
Unique Readers
10
Time Saved
2 min
vs 3 min read
Condensed
90%
419 → 40 words
Want the full story? Read the original article
Read on statnews.com